Lesley Ann Saketkoo, MD, MPH; received her post-graduate degrees and trained in pediatrics and internal medicine at Tulane University and rheumatology at LSU and since January 2015 is an associate professor of medicine in the Department of Medicine at Tulane University. She has held faculty appointments in both pulmonary medicine and rheumatology since returning to New Orleans in 2011 when she established the Scleroderma and Sarcoidosis Patient Care and Research Center (SSPCRC) between Tulane and LSU with internationally recognition; and the Pulmonary Hypertension clinic programs at LSU - which is now transformed into the LSU-Tulane collaborative Comprehensive Pulmonary Hypertension Center, for which she is co-director of clinical research and director of wellness practices. She currently sees patients at TUMC, University Medical Center and the VA.
The SSPRC is a member center and/or a recognized center of excellence by EUSTAR, the Scleroderma Foundation, the Scleroderma Clinical Trials Consortium (SCTC), the Foundation for Sarcoidosis Research (FSR) and the World Association of Sarcoidosis and Other Granulomatous disease (WASOG). With adoption and dedicated sponsorhip by the Tulane Lung Center, the SSPCRC is a Pulmonary Fibrosis Foundation center of excellence. The Tulane Lung Center is the lead North American investigator of the American and European Network of Antisynthetase Syndrome (AENEAS) collaborative group.
Dr. Saketkoo is an internationally recognized researcher, educator and clinician in scleroderma/systemic sclerosis (SSc), sarcoidosis, myositis, pulmonary hypertension (PH) and intestinal lung disease (ILD). She was principal investigator (PI) of the large study (Saketkoo et al, Thorax 2014) that identified the minimal set of outcome measures for connective tissue disease (CTD) related ILD and also for Idiopathic Pulmonary Fibrosis for use in clinical trial; and is the regional PI for PHAROS (PH Assessment and Recognition of Outcomes in Scleroderma) and the NIH sponsored GRASP (Genome Research in African American Scleroderma Patients) study.
Dr. Saketkoo and Dr. Lasky have intensified efforts in SSc inflammation and fibrosis signatures of lung and skin as predictors of severity and therapeutic disease response as well as treatment protocols in CTD-ILD. Dr. Saketkoo and Dr. Hana Safah from Tulane Bone Marrow Transplant Program are dedicated to decreasing treatment related mortality and complications in stem cell transplantation. She is PI in development of a patient-reported outcome measure in SSc-related calcinosis, investigations into treatment effects of mycophenolate in SSc-ILD related PH, and epidemiological studies investigating incidence and environmental exposure.
Dr. Saketkoo is has also trained at the Karolinska Institutet (KI) in Stockholm, making New Orleans the first city in the US to offer semi-open muscle biopsy. Currently Dr. Saketkoo is Vice-Chair of the IMACS (International Myositis and Clinical Studies Group) planning committee. As well as task force member for the EUSTAR-SCTC Myopathy Group and international cohort.
Dr. Saketkoo, with the University of Utah, is establishing the first international clinical registry in Sarcoidosis as well as leading efforts in sarcoidosis to develop screening protocols to prevent morbidity and mortality, identify outcome measures for clinical practice and clinical trials as well as for recommendations for pulmonary rehabilitation.
Dr. Saketkoo leads international and local workshops for patients and medical professionals in 'Mindfulness in Medicine' as well as a teaching program of safe self-paced exercise for patients with cardiopulmonary disease and other chronic illness.
Her other clinical interests include vasculitis and systemic lupus erythematosus.
Saketkoo LA, Magnus JH, Doyle MK. The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope. Am J Med Sci 2014 Jan;347(1):54-63.
- Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL. Connective Tissue Disease-Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J Rheumatol 2014 Apr;41(4):792-8.
- Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202.
- Saketkoo LA, Distler O. Is there evidence for vasculitis in systemic sclerosis? Curr Rheumatol Rep 2012 Dec;14(6):516-25. doi: 10.1007/s11926-012-0296-9.
Kirwan JR, Boers M, Hewlett S, Beaton D, Bingham CO 3rd, Choy E, Conaghan PG, D'Agostino MA, Dougados M, Furst DE, Guillemin F, Gossec L, van der Heijde DM, Kloppenburg M, Kvien TK, Landewé RB, Mackie SL, Matteson EL, Mease PJ, Merkel PA, Ostergaard M, Saketkoo LA, Simon L, Singh JA, Strand V, Tugwell P.Updating the OMERACT filter: core areas as a basis for defining core outcome sets. J Rheumatol2014 May;41(5):994-9.